产品说明书

Ximelagatran

Print
Chemical Structure| 192939-46-1 同义名 : H 376/95;Exanta;Exarta;H 376-95
CAS号 : 192939-46-1
货号 : A734242
分子式 : C24H35N5O5
纯度 : 98%+
分子量 : 473.565
MDL号 : MFCD05861056
存储条件：

粉末 Inert atmosphere,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 250 mg/mL(527.91 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
描述 Ximelagatran is an orally active thrombin inhibitor that selectively and competitively inhibits free or clot-bound thrombin. Ximelagatran can be used as an anticoagulant with rapid onset of action, predictable, dose-dependent pharmacokinetic and pharmacodynamic properties[1][2].Ximelagatran is currently being used in the development of anticoagulants for the prevention and treatment of thromboembolism. Ximelagatran is rapidly absorbed and rapidly converted to its active form, Melagatran. Preliminary studies have demonstrated the efficacy and safety of Ximelagatran in the prevention of venous thromboembolism following total knee or total hip arthroplasty[3]. .
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.11mL

0.42mL

0.21mL

10.56mL

2.11mL

1.06mL

21.12mL

4.22mL

2.11mL
参考文献

[1]Colwell CW Jr, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost. 2003 Oct;1(10):2119-30.

[2]Gao JH, et al. Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis. Medicine (Baltimore). 2017 Oct;96(40):e8059.

[3]Francis CW, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med. 2003 Oct 30;349(18):1703-12.